Results 11 to 20 of about 14,309 (181)

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

Annals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD   +7 more
doaj   +1 more source

SIDE EFFECTS OF VARIOUS SCHEMES OF INTERFERON THERAPY OF CHRONIC HEPATITIS C AND THEIR CORRECTION

Медицинский совет, 2017
The aim of this work was to assess the frequency and severity of major interferon-induced side effects depending on the applied interferon drug. The study included 29 patients with chronic hepatitis C with genotype 1b, 2, 3a/b.
A. M. Ryumin, O. L. Sobolevskaya, O. V. Korochkina   +2 more
doaj   +1 more source

Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study Esquema de indução diário com interferon alfa 2-a ou alfa 2-b em combinação com ribavirina para tratamento da hepatite crônica C: estudo prospectivo randomizado

Arquivos de Gastroenterologia, 2006
BACKGROUD: Studies on hepatitis C virus kinetics showed that serum levels of interferon fall 48 h after drug administration, when viral load is increasing again.
Eduardo Lorens Braga, André Castro Lyra, Lourianne Nascimento, Eduardo Netto, Luciano Kalabrik, Luiz Guilherme Costa Lyra   +5 more
doaj   +1 more source

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Viruses, 2022
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis.
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen   +3 more
doaj   +1 more source

Tratamento de hemangioma gigante com interferon alfa: relato de dois casos Treatment of giant hemangioma with interferon-alpha: report of two cases

Revista Brasileira de Hematologia e Hemoterapia, 2007
O objetivo do trabalho é descrever o uso de interferon alfa no tratamento de pacientes com hemangioma gigante. Os autores relatam e analisam dois casos de hemangioma gigante em tratamento com interferon alfa. IBS, 3 anos, em acompanhamento no Ambulatório
Ana Julia Balau, Livia C. De Nadai, Mônica S. Bressan, Josiane L. Simão   +3 more
doaj   +1 more source

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a

Jornal de Pediatria, 2001
OBJETIVO: descrever os resultados obtidos com o uso do alfa-2a-interferon no tratamento de pacientes pediátricos com linfangiomas irressecáveis ou refratários a outros tratamentos.
Reynaldo J.S.P. de Souza, Luiz G. Tone
doaj   +1 more source

Adjuvant Interferon Alfa for Melanoma

Current Oncology, 2010
The author poses the question “Why did these study results not lead to a global consensus about interferon treatment as standard of care?” [...]
Kenneth S, Wilson, Andrew, Attwell
openaire   +2 more sources

Interferon alfa-associated retinopathy

Journal of Osteopathic Medicine, 1997
Abstract Interferon alia and its related compounds have been used for more than 10 years in the treatment of a number of conditions including viral illnesses, childhood hemangiomas, various cancers, and leukemia. The potential applications for this class of medication continue to grow. The use of interferon alia in experimental protocols
R B, Chambers, A, Downie, B, Foote, F H, Davidorf   +3 more
openaire   +2 more sources

Erdheim Chester disease: a subtle quiddity; the first case reported from Nepal

Radiology Case Reports, 2020
Erdheim-Chester disease (ECD) is a rare entity throughout the world. This is the first case reported in Nepal. ECD is a rare aggressive, non-Langerhan's histocytosis of unknown origin with classical histological features.
Pawan Singh, MBBS, Roshani Shrestha, Narendra Kumar Yadav   +2 more
doaj   +1 more source